SEC Form 4 · accession 0001209191-15-051546
SYNAGEVA BIOPHARMA CORP · GEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sanj K Patel
Officer — President & CEO · Director
Period of report
Jun 5, 2015
Accepted (ET)
Jun 9, 2015 · 6:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000911326
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 5, 2015 | A | 72,000 | $0.00 | A | 73,031 | D | |
| Common StockF2 | holding | — | — | — | 286 | I | Held by Abbey Road Investment Group |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Award of Restricted Stock Units under the 2014 Equity Incentive Plan. Vests (x) 25% on June 5, 2016 and (y) 12.5% per six months thereafter.
- F2The reporting person has sole voting and investment power over the securities and disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein.